knowledge -WSS

knowledge

author：fashion 2025-09-14 14:39:32 - browse：13

Boston Scientific headquarters -- Health coverage from STAT — Boston Scientific is growing its urology portfolio with the Axonics acquisition. Steven Senne/AP

Boston Scientific said it will buy Axonics, a device company treating urinary and bowel disorders, on Monday. The deal is worth $3.7 billion.

It’s the first billion-dollar medical device deal of 2024 — a rare occurrence in 2023, which saw just a handful of medtech acquisitions reaching the billion threshold. Boston Scientific said it expects to close the deal in the first half of this year. Axonics’ stock increased by 20% in light of the news; Boston Scientific’s dropped slightly.

Boston Scientific has acquired companies across all medtech sectors in the past year. The device maker bought Apollo Endosurgery, a company selling surgical tools to combat obesity, for $615 million in 2023. In September of 2023, Boston Scientific bought pain relief company Relievant for $850 million.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Global cancer cases to surge 77% by 2050, WHO report says

focus

WSS

Devoted Health’s losses in Medicare Advantage persist

Gene therapy denied for Afghan refugee whose father aided U.S.

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

hotspot

knowledge

knowledge

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Merck to acquire Harpoon Therapeutics for $680 million

Hollywood unions extend contract negotiations for actors

Male doctors called my cancer incurable. A female doctor showed it wasn't

Psychedelics group wrestles with new pharma identity

Medicare Advantage overpayments discussion gets experts fired up

DIEP, the 'gold standard' of breast reconstruction, is under threat

FDA early review: GLP

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

leisure time

A single Democrat is willing to weaken Medicare negotiation power

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Study suggests new cause of Down syndrome: cells linked to aging

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

Rune Labs, whose app tracks Parkinson's symptoms, raises $12M

Gene therapy for Afghan refugees’ infant will be fully covered

explore

focus

focus

focus